Literature DB >> 12860912

Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy.

Sara L Van Driest1, Erik G Ellsworth, Steve R Ommen, A Jamil Tajik, Bernard J Gersh, Michael J Ackerman.   

Abstract

BACKGROUND: Thin filament mutations are reported to cause approximately 20% of cases of hypertrophic cardiomyopathy (HCM), and they have been associated with specific phenotypes. However, the frequency of these mutations and their associated phenotype(s) from a large tertiary referral center population are unknown. METHODS AND
RESULTS: DNA was obtained from 389 unrelated patients with HCM. A mutational analysis of all protein coding exons of cardiac troponin T, cardiac troponin I, alpha-tropomyosin, and cardiac actin was performed using polymerase chain reaction, denaturing high-performance liquid chromatography, and DNA sequencing. The clinical data were extracted from patient records and maintained independent of the patient genotype. Overall, only 18 patients (4.6%) harbored isolated thin filament mutations: 8 had troponin T mutations, 6 had troponin I mutations, 3 had alpha-tropomyosin mutations, and 1 had an actin mutation. Of the 12 unique missense mutations identified, 9 (75%) were novel mutations. As a group, patients with thin filament mutations were not significantly different from the rest of the cohort in age at diagnosis, left ventricular wall thickness, left ventricular outflow tract obstruction, or family history of HCM or sudden cardiac death.
CONCLUSIONS: Mutations in genes encoding thin filament proteins are less prevalent in HCM than previously estimated. Patients with mutations in troponin T, troponin I, alpha-tropomyosin, and actin do not invariably present with any distinct clinical feature, thus limiting the utility of gene status for risk stratification or of clinical phenotype in guiding individual genetic screening at this time.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860912     DOI: 10.1161/01.CIR.0000080896.52003.DF

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  68 in total

1.  Functional characterization of the human α-cardiac actin mutations Y166C and M305L involved in hypertrophic cardiomyopathy.

Authors:  Mirco Müller; Antonina Joanna Mazur; Elmar Behrmann; Ralph P Diensthuber; Michael B Radke; Zheng Qu; Christoph Littwitz; Stefan Raunser; Cora-Ann Schoenenberger; Dietmar J Manstein; Hans Georg Mannherz
Journal:  Cell Mol Life Sci       Date:  2012-05-29       Impact factor: 9.261

Review 2.  Hypertrophic cardiomyopathy.

Authors:  Carolyn Y Ho
Journal:  Heart Fail Clin       Date:  2010-04       Impact factor: 3.179

3.  Myofilament Ca sensitization increases cytosolic Ca binding affinity, alters intracellular Ca homeostasis, and causes pause-dependent Ca-triggered arrhythmia.

Authors:  Tilmann Schober; Sabine Huke; Raghav Venkataraman; Oleksiy Gryshchenko; Dmytro Kryshtal; Hyun Seok Hwang; Franz J Baudenbacher; Björn C Knollmann
Journal:  Circ Res       Date:  2012-05-29       Impact factor: 17.367

4.  Structure of the mid-region of tropomyosin: bending and binding sites for actin.

Authors:  Jerry H Brown; Zhaocai Zhou; Ludmilla Reshetnikova; Howard Robinson; Rama D Yammani; Larry S Tobacman; Carolyn Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 5.  Nuclear tropomyosin and troponin in striated muscle: new roles in a new locale?

Authors:  P Bryant Chase; Mark P Szczypinski; Elliott P Soto
Journal:  J Muscle Res Cell Motil       Date:  2013-08-02       Impact factor: 2.698

6.  Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy.

Authors:  Yubao Zou; Jizheng Wang; Xuan Liu; Yilu Wang; Yi Chen; Kai Sun; Shuo Gao; Channa Zhang; Zhimin Wang; Yin Zhang; Xinxing Feng; Ying Song; Yajie Wu; Hongju Zhang; Lei Jia; Hu Wang; Dong Wang; Chaowu Yan; Minjie Lu; Xianliang Zhou; Lei Song; Rutai Hui
Journal:  Mol Biol Rep       Date:  2013-01-03       Impact factor: 2.316

7.  Using baculovirus/insect cell expressed recombinant actin to study the molecular pathogenesis of HCM caused by actin mutation A331P.

Authors:  Fan Bai; Hannah M Caster; Peter A Rubenstein; John F Dawson; Masataka Kawai
Journal:  J Mol Cell Cardiol       Date:  2014-04-30       Impact factor: 5.000

8.  The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.

Authors:  Martin Penicka; Pavel Gregor; Roman Kerekes; Dan Marek; Karol Curila; Jiri Krupicka
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

9.  Formin homology 2 domain containing 3 variants associated with hypertrophic cardiomyopathy.

Authors:  Eric C Wooten; Virginia B Hebl; Matthew J Wolf; Sarah R Greytak; Nicole M Orr; Isabelle Draper; Jenna E Calvino; Navin K Kapur; Martin S Maron; Iftikhar J Kullo; Steve R Ommen; J Martijn Bos; Michael J Ackerman; Gordon S Huggins
Journal:  Circ Cardiovasc Genet       Date:  2012-12-19

10.  Structural and kinetic effects of hypertrophic cardiomyopathy related mutations R146G/Q and R163W on the regulatory switching activity of rat cardiac troponin I.

Authors:  Zhiqun Zhou; Daniel Rieck; King-Lun Li; Yexin Ouyang; Wen-Ji Dong
Journal:  Arch Biochem Biophys       Date:  2012-12-13       Impact factor: 4.013

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.